Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roivant Sciences Ltd (NQ: ROIV )

12.28 +0.46 (+3.85%)
Streaming Delayed Price Updated: 11:44 AM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Roivant Sciences Ltd

< Previous 1 2 Next >
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024
From Roivant Sciences
Via GlobeNewswire
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
The acquisition expands Organon’s dermatology capabilities with a nonbiologic, non-steroidal topical treatment in the U.S. 
From Roivant Sciences
Via GlobeNewswire
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
From Roivant Sciences
Via GlobeNewswire
Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress
From Roivant Sciences
Via GlobeNewswire
Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator
From Roivant Sciences
Via GlobeNewswire
Roivant Provides Update on Graves’ Disease Development Program
From Roivant Sciences
Via GlobeNewswire
Roivant Reports Financial Results for the First Quarter Ended June 30, 2024, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Roivant to Report Financial Results for the First Quarter Ended June 30, 2024, and Provide Business Update on Thursday, August 8, 2024
From Roivant Sciences
Via GlobeNewswire
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024
From Roivant Sciences
Via GlobeNewswire
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
From Roivant Sciences
Via GlobeNewswire
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024
From Roivant Sciences
Via GlobeNewswire
Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
From Roivant Sciences
Via GlobeNewswire
Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease
From Roivant Sciences
Via GlobeNewswire
Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
From Roivant Sciences
Via GlobeNewswire
Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus
From Roivant Sciences
Via GlobeNewswire
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors
From Roivant Sciences
Via GlobeNewswire
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023
From Roivant Sciences
Via GlobeNewswire
Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant
From Roivant Sciences
Via GlobeNewswire
Covant Therapeutics Appoints Vincent Hennemand as Chief Executive Officer
From Covant Therapeutics
Via GlobeNewswire
Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results
From Roivant Sciences
Via GlobeNewswire
Roivant Announces Completion of Redemption of its Outstanding Warrants
From Roivant Sciences
Via GlobeNewswire
Roivant Announces Redemption Fair Market Value in Connection with Redemption of its Outstanding Warrants
From Roivant Sciences
Via GlobeNewswire
Roivant Reports Financial Results for the First Quarter Ended June 30, 2023, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Roivant to Report Financial Results for the Quarter Ended June 30, 2023, and Provide Business Update on Monday, August 14, 2023
From Roivant Sciences
Via GlobeNewswire
Roivant Announces Redemption of Outstanding Warrants
From Roivant Sciences
Via GlobeNewswire
Telavant, a Roivant Company, Advances Inflammatory Bowel Disease Program with First Patient Dosed in Global Phase 2 Trial of Novel Anti-TL1A Antibody RVT-3101 in Crohn’s Disease
From Roivant Sciences
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.